PhaseBio Pharmaceuticals Net Income

Net Income of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Income growth rates and interactive chart. Net income (NI), also called net earnings, is calculated as sales minus cost of goods sold, selling, general and administrative expenses, operating expenses, depreciation, interest, taxes, and other expenses. It is the profit available to all shareholders, both preferred and common.


Highlights and Quick Summary

  • Net Income for the quarter ending September 29, 2021 was $-31.9 Million (a 11.31% increase compared to previous quarter)
  • Year-over-year quarterly Net Income increased by 5.1%
  • Annual Net Income for 2020 was $-98.6 Million (a 151.14% increase from previous year)
  • Annual Net Income for 2019 was $-39.2 Million (a 64.59% increase from previous year)
  • Annual Net Income for 2018 was $-23.8 Million (a 132.71% increase from previous year)
  • Twelve month Net Income ending September 29, 2021 was $-118 Million (a 6.08% increase compared to previous quarter)
  • Twelve month trailing Net Income increased by 20.06% year-over-year
Trailing Net Income for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-118 Million $-112 Million $-111 Million $-98.6 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Income of PhaseBio Pharmaceuticals

Most recent Net Incomeof PHAS including historical data for past 10 years.

Interactive Chart of Net Income of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Net Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-31.92 $-28.68 $-27.36
2020 $-30.38 $-25.14 $-28.14 $-14.91 $-98.57
2019 $-11.33 $-11.39 $-9.23 $-7.29 $-39.25
2018 $-4.87 $-7.9 $-6.67 $-4.4 $-23.85
2017 $-2.54 $-7.71 $-10.25
2016 $-9.22

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.